95 results
Page 2 of 5
8-K
EX-99.1
foe00uztpefhr
8 Nov 22
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
6ibwkrt9884jpd8a59g
8 Aug 22
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
4:32pm
8-K
EX-99.1
cbafti
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
EX-99.1
i20 gjji5
16 Jun 22
Other Events
7:00am
8-K
EX-99.1
cy2 q3f4g26
9 May 22
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
4:31pm
POS AM
3q4dn t4130jnxd
28 Feb 22
Prospectus update (post-effective amendment)
5:46pm
8-K
EX-99.1
4wy1g
28 Feb 22
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
4:36pm
POSASR
xpvf7unc
28 Feb 22
Automatic shelf registration (post-effective amendment)
4:16pm
8-K
EX-99.1
f2dmwhh
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
ddcopc5 yuvul
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.1
v4rtixewdhqk7
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm